Form 4: Kymera Therapeutics COO Jeremy Chadwick Reports Stock Transactions

Chief Operating Officer of Kymera Therapeutics, Jeremy Chadwick, reports acquisition and disposal of common stock and stock options on March 3, 2025.

Summary

• On March 3, 2025, Jeremy Chadwick, the Chief Operating Officer of Kymera Therapeutics, reported transactions involving the company's stock.
• Chadwick acquired 25,000 shares of common stock through restricted stock units (RSUs) at a price of $0.
• He also disposed of 1,131 shares at an average price of $30.3271 and 252 shares at an average price of $31.0046 to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Chadwick beneficially owns 67,800 shares of common stock.
• Additionally, Chadwick acquired a stock option for 50,000 shares of common stock with an exercise price of $30.17, expiring on March 2, 2035.
• The RSUs vest in three equal annual installments starting March 3, 2025, and the stock options vest in 36 equal monthly installments from the same date, both contingent upon continued employment.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions related to executive compensation. The acquisition of RSUs and stock options is a positive sign, but the sale of shares to cover taxes is a neutral event.

Positives

• Acquisition of 25,000 shares through RSUs indicates confidence in the company's future.
• Grant of stock options incentivizes continued employment and performance.

Negatives

• Sale of shares to cover tax obligations, although automatic, could be perceived negatively if substantial.

Risks

• Vesting of RSUs and stock options is contingent upon continued employment, creating a potential risk if Chadwick leaves the company.
• Automatic sales to cover tax obligations could exert downward pressure on the stock price.

Future Outlook

The vesting schedules for RSUs and stock options suggest a long-term commitment from the executive, aligning his interests with those of the shareholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future performance.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices in the biotechnology industry to attract and retain talent.
• Vesting schedules are typically structured to incentivize long-term performance and alignment with shareholder value, similar to practices at companies like Amgen, Biogen, and Vertex Pharmaceuticals.

Stakeholder Impact

• Shareholders may view the acquisition of RSUs and stock options as a positive sign of management's commitment.
• Employees may be motivated by the executive's continued investment in the company.

Key Dates